Company description

Agenus Inc. (AGEN) is a biotechnology company that focuses on discovering, developing, and commercializing innovative immunotherapies for the treatment of cancer and other diseases. Founded in 1994, Agenus has established itself as a pioneer in the field of immunotherapy, with a portfolio of over a dozen clinical and pre-clinical products in development. The company's lead product, Prophage, is a personalized cancer vaccine that has shown promising results in treating glioblastoma, a deadly form of brain cancer. In addition, Agenus has several other cancer immunotherapies in development, including checkpoint inhibitors and adjuvants, which are designed to work in combination with Prophage to enhance its effectiveness. Beyond cancer, Agenus is also exploring the potential of its technologies in treating infectious diseases, autoimmune disorders, and other chronic conditions. With a diverse and growing pipeline and partnerships with major pharmaceutical companies, Agenus is well-positioned to continue making groundbreaking advancements in the field of immunotherapy and improving the lives of patients worldwide.